Retatrutide Weight Loss: How Much At Each Dose

https://www.otplinks.com

0:00 Welcome & today’s focus: Retatrutide and “chasing the biggest number”
1:11 On The Pen intro, live schedule (Mon/Wed/Fri) & housekeeping
2:10 How Dave first heard about retatrutide (work trip, early phase 1 data)
3:35 Flashback clip: early excitement about retatrutide phase 3 trials
4:40 Why this new retatrutide data feels different for obesity medicine
5:32 TRIUMPH-4 trial overview: obesity + knee osteoarthritis population
7:00 Headline results: 28.7% average weight loss, surgery-level efficacy
8:47 Breaking down weight loss by dose (9 mg vs 12 mg; 25–35% loss rates)
11:05 What “efficacy estimate” really means (race-track analogy)
13:28 Real-world view: treatment-regimen estimate (20–23.7%) vs trial ideal
15:40 Mechanism refresher: GIP, GLP-1, glucagon and why RETA differs from TIRZ
18:05 Side effects, dysesthesia/allodynia & who stopped treatment (BMI differences)
21:02 Why the lower doses matter & who actually needs 30% weight loss
24:15 From “just make the scale go down” to quality of weight loss & body composition
28:05 Future focus: health, longevity, and peptides beyond hitting goal weight
30:40 Viewer Q&A: combining RETA + TIRZ, amylin (eloralintide) combos & “talk to your doctor”
34:38 How retatrutide changes the next decade of obesity treatment conversations
37:22 News update: high-dose Wegovy 7.2 mg approval in the EU & US outlook
40:55 Orforglipron oral GLP-1: liver-signal concerns & fast-track FDA review
45:20 Why small-molecule oral GLP-1s aren’t the same as injectable peptides
48:40 New topic: Indiana “Safe Drug Act of 2025” and why Dave is concerned
51:02 Production caps, “essentially a copy” language & shifting power from prescribers to FDA
54:28 How the bill undermines personalization while ignoring real safety tools
57:05 Safety theater vs real safeguards: API sourcing, sterility & adverse-event reporting
59:45 Who actually gets hit: compliant 503A/503B compounders vs existing bad actors
1:02:05 Call to action: petition at otplinks.com & why patient voices matter
1:05:10 Change.org impact, media attention & centering the patient perspective
1:07:30 Final Q&A, subscribe, obesity.news email list & closing thanks

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.